AP
APUS
Apimeds Pharmaceuticals US, Inc.
$1.38
-0.71%
$17.5M
No data for this timeframe.
Vol
Market Cap$17.5M
Cap SizeNano Cap
Inst. Holders2 funds
Inst. Value$96.8K
Inst. Activity1 buys / 1 sells
SEC Reports3
Recent Activity
May 5, 2026
SEC
Apimeds Pharmaceuticals US appointed Sungjoon Chae as Co-CEO effective May 4, 2026, following a stockholder nomination.
8-K — Impact 2/10
May 5, 2026
short_volume
Short Volume: APUS — 57.4% short (1.1M / 1.9M)
Short: 1,062,311 | Exempt: 4,085 | TRF Vol: 1,850,006 | Short Ratio: 57.4% | Off-exchange volume (da
May 4, 2026
SEC
APUS filed an 8-K detailing a comprehensive settlement resolving shareholder disputes and a forbearance agreement with i
8-K — Impact 7/10
Apr 16, 2026
SEC
Apimeds Pharmaceuticals failed to file its 2025 Form 10-K on time and expects to miss the 15-day extension, triggering a
8-K — Impact 7/10
Inst.
BANK OF AMERICA CORP — ADD
40 shares ($66.00)
Inst.
RENAISSANCE TECHNOLOGIES LLC — EXIT
0 shares ($0.00)
Latest Reports
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $96.7K | NEW |
| BANK OF AMERICA CORP | $66.00 | ADD |
2 institutional holders with $96.8K total value (59,032 shares) as of 2025-Q4. Top holders: VANGUARD, BANK.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 58,992 | $96.7K | 99.9% | NEW |
| 2 | BANK OF AMERICA CORP /DE/ | 40 | $66.00 | 0.1% | ADD +37.9% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| BANK OF AMERICA CORP /DE/ | ADD | 29 | 40 | +37.9% | $66.00 | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | EXIT | 27,893 | 0 | -100.0% | $0.00 | 2025-Q4 |
| VANGUARD GROUP INC | NEW | — | 58,992 | — | $105.0K | 2025-Q3 |
| RENAISSANCE TECHNOLOGIES LLC | NEW | — | 27,893 | — | $49.6K | 2025-Q3 |
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
3 SEC filing reports analyzed. Sentiment: 0 bullish, 2 bearish, 0 mixed, 1 neutral. Avg impact: 5.3/10.
NEUTRAL
8-K
2/10
Apimeds Pharmaceuticals US appointed Sungjoon Chae as Co-CEO effective May 4, 2026, following a stoc
May 5, 2026
BEARISH
8-K
7/10
APUS filed an 8-K detailing a comprehensive settlement resolving shareholder disputes and a forbeara
May 4, 2026
BEARISH
8-K
7/10
Apimeds Pharmaceuticals failed to file its 2025 Form 10-K on time and expects to miss the 15-day ext
Apr 16, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next Q | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Current FY | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next FY | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 5, 2026
short_volume
Short Volume: APUS — 57.4% short (1.1M / 1.9M)
Short: 1,062,311 | Exempt: 4,085 | TRF Vol: 1,850,006 | Short Ratio: 57.4% | Off-exchange volume (dark pool + OTC)